Enzo Biochem, Inc. (ENZ)
Largest Insider Buys in Sector
ENZ Stock Price History Chart
ENZ Stock Performance
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Insider Activity of Enzo Biochem, Inc.
Over the last 12 months, insiders at Enzo Biochem, Inc. have bought $0 and sold $0 worth of Enzo Biochem, Inc. stock.
On average, over the past 5 years, insiders at Enzo Biochem, Inc. have bought $261,776 and sold $2.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $12,875 was made by Wolf James G. () on 2023‑02‑13.
List of Insider Buy and Sell Transactions, Enzo Biochem, Inc.
| 2023-02-13 | 10,000 0.0208% | $1.29 | $12,875 | +10.83% | ||||
| 2023-02-10 | 5,000 0.0103% | $1.29 | $6,450 | +9.30% | ||||
| 2023-01-27 | director | 11,800 0.024% | $1.40 | $16,520 | 0.00% | |||
| 2022-11-23 | Chief Executive Officer | 100,000 0.2052% | $1.97 | $197,000 | -24.37% | |||
| 2022-11-01 | director | 8,500 0.0172% | $2.14 | $18,225 | -28.57% | |||
| 2022-10-31 | director | 14,500 0.0299% | $2.15 | $31,175 | -27.57% | |||
| 2022-07-15 | Chief Operating Officer | 2,500 0.0052% | $2.42 | $6,050 | -9.17% | |||
| 2022-07-12 | 12,500 0.0243% | $2.27 | $28,375 | -9.17% | ||||
| 2022-07-05 | 120,000 0.2362% | $2.20 | $264,000 | -4.78% | ||||
| 2022-06-15 | 75,000 0.1523% | $2.20 | $165,000 | -1.35% | ||||
| 2022-06-15 | Chief Executive Officer | 4,600 0.0093% | $2.19 | $10,074 | -1.35% | |||
| 2022-06-14 | Chief Financial Officer | 3,500 0.0074% | $2.15 | $7,525 | +4.76% | |||
| 2021-03-16 | Sale | 10 percent owner | 300,000 0.706% | $4.65 | $1.39M | -19.61% | ||
| 2021-03-15 | Sale | 10 percent owner | 144,768 0.4879% | $4.83 | $698,840 | +10.81% | ||
| 2020-02-18 | 10 percent owner | 4,000 0.0082% | $2.20 | $8,800 | +7.14% | |||
| 2020-02-14 | 10 percent owner | 6,000 0.0125% | $2.21 | $13,260 | +7.66% | |||
| 2019-08-20 | 10 percent owner | 9,700 0.0202% | $3.11 | $30,167 | -16.24% | |||
| 2019-08-16 | 10 percent owner | 22,800 0.0456% | $3.06 | $69,768 | -18.32% | |||
| 2019-07-23 | 10 percent owner | 409,200 0.87% | $3.65 | $1.49M | -24.93% | |||
| 2019-07-22 | 10 percent owner | 9,644 0.0201% | $3.64 | $35,104 | -26.36% |
Insider Historical Profitability
| HARBERT MANAGEMENT CORP | 10 percent owner | 5175913 9.9072% | $1.03 | 8 | 2 | <0.0001% |
| Radoff Bradley Louis | 4194663 8.029% | $1.03 | 3 | 0 | <0.0001% | |
| Wolf James G. | 4100000 7.8478% | $1.03 | 5 | 0 | <0.0001% | |
| RABBANI ELAZAR | Chm of the Bd, CEO and Sec | 1848668 3.5385% | $1.03 | 2 | 3 | +1.13% |
| RABBANI SHAHRAM K | Treasurer, Secretary | 1828494 3.4999% | $1.03 | 1 | 5 | <0.0001% |
| WEINER BARRY W | President, CFO, Treasurer, PAO | 1302111 2.4924% | $1.03 | 1 | 3 | <0.0001% |
| Erfanian Hamid | Chief Executive Officer | 374600 0.717% | $1.03 | 2 | 0 | <0.0001% |
| Perlysky Dov | director | 266235 0.5096% | $1.03 | 1 | 1 | +0.29% |
| BORTZ GREGORY M. | director | 250870 0.4802% | $1.03 | 0 | 1 | |
| ENGELHARDT DEAN | Executive Vice President | 153651 0.2941% | $1.03 | 0 | 6 | |
| KELKER NORMAN E | Senior Vice President | 104583 0.2002% | $1.03 | 0 | 4 | |
| THALENFELD BARBARA E | VP, Corporate Development | 60813 0.1164% | $1.03 | 1 | 5 | <0.0001% |
| LAZAR MELVIN F | director | 50375 0.0964% | $1.03 | 5 | 0 | <0.0001% |
| Hanna Bruce A. | director | 37816 0.0724% | $1.03 | 1 | 0 | +0.29% |
| O'Brien James Michael | EVP of Finance | 28187 0.054% | $1.03 | 0 | 2 | |
| BALEZENTIS CARL W | Pres., Enzo Life Sciences | 25950 0.0497% | $1.03 | 0 | 3 | |
| CLEMENS PETER J IV | 10 percent owner | 15000 0.0287% | $1.03 | 2 | 0 | +7.4% |
| Kent Stephen B H | director | 9654 0.0185% | $1.03 | 0 | 5 | |
| KRENITSKY KEVIN | President, Enzo Clinical Labs | 6600 0.0126% | $1.03 | 1 | 0 | <0.0001% |
| Bench David | Chief Financial Officer | 6000 0.0115% | $1.03 | 1 | 0 | +4.76% |
| Cannon Kara | Chief Operating Officer | 2500 0.0048% | $1.03 | 1 | 0 | <0.0001% |
| KASTEN BERNARD L | director | 0 0% | $1.03 | 0 | 5 | |
| WARSHAWSKY STANFORD S | 0 0% | $1.03 | 2 | 2 | <0.0001% |
Institutional Investor Ownership
| HARBERT FUND ADVISORS, INC. | $6.57M | 10.06 | 5.18M | 0% | +$0 | 4.77 | |
| Renaissance Technologies | $3.09M | 4.73 | 2.44M | -1.78% | -$55,970.81 | 0.01 | |
| The Vanguard Group | $2.38M | 3.65 | 1.88M | 0% | +$0 | <0.0001 | |
| Tang Capital Management, LLC | $1.6M | 2.45 | 1.26M | -25.88% | -$558,783.66 | 0.01 | |
| BlackRock | $1.21M | 1.85 | 953,991 | +0.03% | +$411.48 | <0.0001 | |
| Dimensional Fund Advisors | $832,860.00 | 1.27 | 655,795 | -10.13% | -$93,836.53 | <0.0001 | |
| Geode Capital Management | $429,203.00 | 0.66 | 337,856 | 0% | +$0 | <0.0001 | |
| RBF Capital, LLC | $317,956.00 | 0.49 | 250,359 | 0% | +$0 | 0.01 | |
| Bridgeway Capital Management | $288,417.00 | 0.44 | 227,100 | 0% | +$0 | <0.01 | |
| State Street | $195,757.00 | 0.3 | 154,139 | -7.72% | -$16,383.04 | <0.0001 | |
| Morgan Stanley | $91,129.00 | 0.14 | 71,755 | -5.28% | -$5,080.01 | <0.0001 | |
| Wittenberg Investment Management Inc | $86,364.00 | 0.13 | 68,003 | 0% | +$0 | 0.03 | |
| Northern Trust | $85,418.00 | 0.13 | 67,258 | -40.65% | -$58,506.59 | <0.0001 | |
| T. Rowe Price | $57,000.00 | 0.09 | 44,800 | 0% | +$0 | <0.0001 | |
| Kempner Capital Management Inc | $32,000.00 | 0.05 | 25,475 | 0% | +$0 | 0.02 | |
| Susquehanna International Group | $30,823.00 | 0.05 | 24,270 | New | +$30,823.00 | <0.0001 | |
| 32 Advisors | $25,965.00 | 0.04 | 20,445 | 0% | +$0 | <0.01 | |
| Assenagon Asset Management S.A. | $25,112.00 | 0.04 | 19,773 | -72.69% | -$66,857.38 | <0.0001 | |
| Paradigm Financial Partners Llc | $24,765.00 | 0.04 | 19,500 | 0% | +$0 | 0.01 | |
| Raymond James Trust National Association | $21,610.00 | 0.03 | 17,016 | 0% | +$0 | <0.01 | |
| Shulman Demeo Asset Management | $19,668.00 | 0.03 | 15,487 | 0% | +$0 | 0.01 | |
| Sage Mountain Advisors | $18,028.00 | 0.03 | 14,195 | 0% | +$0 | <0.01 | |
| Xtx Topco Ltd | $18,449.00 | 0.03 | 14,527 | New | +$18,449.00 | <0.0001 | |
| Charles Schwab | $17,108.00 | 0.03 | 13,471 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $15,384.00 | 0.02 | 12,113 | +46.2% | +$4,861.72 | <0.0001 | |
| Nierenberg Investment Management Company Inc | $14,675.00 | 0.02 | 11,555 | 0% | +$0 | 0.01 | |
| Covestor Ltd | $5,000.00 | 0.01 | 3,967 | 0% | +$0 | <0.01 | |
| Bank of America | $3,033.00 | 0.01 | 2,388 | -23.27% | -$919.55 | <0.0001 | |
| Benefit Financial Services Group (BFSG) | $3,573.00 | 0.01 | 2,813 | New | +$3,573.00 | <0.0001 | |
| JPMorgan Chase | $2,328.00 | <0.01 | 1,833 | 0% | +$0 | <0.0001 | |
| Fidelity Investments | $2,521.00 | <0.01 | 1,985 | +361.63% | +$1,974.89 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 1,081 | -17.67% | -$214.62 | <0.0001 | |
| Wells Fargo | $1,121.00 | <0.01 | 882 | -32.26% | -$533.81 | <0.0001 | |
| Advisor Group Holdings Inc | $1,425.00 | <0.01 | 1,123 | 0% | +$0 | <0.0001 | |
| Simplex Trading Llc | $1,000.00 | <0.01 | 881 | New | +$1,000.00 | <0.0001 | |
| UBS | $353.00 | <0.01 | 278 | -85.17% | -$2,026.58 | <0.0001 | |
| Sound Income Strategies | $13.00 | <0.01 | 10 | New | +$13.00 | <0.0001 | |
| Newedge Advisors Llc | $13.00 | <0.01 | 10 | 0% | +$0 | <0.0001 |